CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy

Skeletal Muscle

Table 1 Higher relative numbers of circulating CD4⁺ and CD8⁺ T cell subsets expressing high densities of CD49d in patients with Duchenne muscular dystrophy

T cell subpopulation	Relative cell number (mean ± SD)^a		p value
T cell subpopulation	Healthy	DMD	p value
CD4⁺CD49a^hi	3.66 ± 2.80	4.34 ± 3.18	0.75
CD8⁺CD49a^hi	3.81 ± 3.25	4.02 ± 3.66	0.93
CD4⁺CD49d^hi	23.25 ± 5.86	29.72 ± 8.66	0.007
CD8⁺CD49d^hi	26.28 ± 5.89	34.66 ± 12.00	0.009
CD4⁺CD49e^hi	34.95 ± 9.28	34.97 ± 7.70	0.87
CD8⁺CD49e^hi	31.10 ± 8.17	34.04 ± 13.42	0.46
CD4⁺CD49f^hi	30.53 ± 7.60	27.85 ± 9.37	0.36
CD8⁺CD49f^hi	18.73 ± 5.37	18.34 ± 7.75	0.65
CD4⁺CD11a^hi	22.71 ± 14.23	19.30 ± 12.80	0.60
CD8⁺CD11a^hi	38.31 ± 11.39	44.64 ± 11.30	0.33

^aData are presented as relative cell numbers of T cell subsets expressing high levels of a given integrin subunit. Numbers in italics illustrate statistically significant differences between normal subjects and Duchenne muscular dystrophy (DMD) patients, with corresponding p values

ISSN: 2044-5040